Abstract
Treatment of advanced BRAF-mutant cutaneous melanoma has undergone several breakthroughs, not only in terms of new therapeutic strategies but also in the number of drugs available. The BRAF–MEK inhibitor combinations vemurafenib plus cobimetinib and dabrafenib plus trametinib have been shown to improve overall survival along with pembrolizumab and nivolumab in monotherapy and when combined with ipilimumab. 1 Luke JJ Flaherty KT Ribas A Long GV Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14: 463-482 Crossref PubMed Scopus (737) Google Scholar Now, another treatment option can be added to the list: encorafenib plus binimetinib. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialThe combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
